Natco Pharma

When is the next results date for Natco Pharma?

No Upcoming Board Meetings

What does Natco Pharma do?

Natco Pharma Ltd. is a mid-cap pharmaceutical company focused on developing and manufacturing pharmaceutical products, with recent quarterly net sales of ₹1,221 Cr and a net profit of ₹407 Cr. The company has a market cap of ₹15,407 Cr and key metrics include a P/E ratio of 8.00 and a return on equity of 24.79%.

Overview:<BR>Natco Pharma Ltd. is a mid-cap company operating in the Pharmaceuticals & Biotechnology industry, focusing on the development and manufacturing of pharmaceutical products.<BR><BR>History:<BR>Natco Pharma Limited was originally incorporated in 1981 as Natco Fine Pharmaceuticals Private Limited. It became a deemed public company in 1992 and changed its name to Natco Pharma Limited in 1993. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,221 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 407 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 15,407 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 8.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.69%<BR>- Debt Equity: -0.29<BR>- Return on Equity: 24.79%<BR>- Price to Book: 2.03<BR><BR>Contact Details:<BR>Address: Natco House, Road No 2 Banjara Hills Hyderabad Telangana : 500033<BR>Tel: 91-040-23547532<BR>Email: investors@natcopharma.co.in<BR>Website: http://www.natcopharma.co.in

Who are in the management team of Natco Pharma?

As of March 2023, the management team of Natco Pharma includes V C Nannapaneni (Managing Director), G S Murthy (Chairman), Rajeev Nannapaneni (CEO), and several other directors and executives responsible for the company's strategic direction and operations.

As of March 2023, the management team of Natco Pharma includes the following key individuals:<BR><BR>1. V C Nannapaneni - Managing Director<BR>2. G S Murthy - Chairman & Independent Director<BR>3. Rajeev Nannapaneni - Director & Chief Executive Officer<BR>4. T V Rao - Non-Executive & Independent Director<BR>5. D G Prasad - Non-Executive & Independent Director<BR>6. Leelaa Digumarti - Non-Executive & Independent Director<BR>7. PSRK Prasad - Vice President & Director<BR>8. MUR Naidu - Non-Executive & Independent Director<BR>9. D Linga Rao - President & Director<BR>10. Pavan Bhat - Vice President & Director<BR>11. Venkat Ramesh - Company Secretary & Compliance Officer<BR><BR>This diverse team is responsible for overseeing the strategic direction and operations of the company.

Who are the peers of the Natco Pharma?

Natco Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Blue Jet Health, Sai Life, Neuland Labs, Sanofi India, and Granules India. In terms of performance, Divi's Lab leads with a 1-year return of 51.69%, while Natco Pharma has a return of -13.51%.

Peers: The peers of Natco Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Blue Jet Health, Sai Life, Neuland Labs., Sanofi India, and Granules India.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Blue Jet Health, Neuland Labs., and Granules India, while Good management risk is found at Divi's Lab., Torrent Pharma, and Sai Life. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good growth is noted for Natco Pharma and Sai Life. Below Average growth is seen at Divi's Lab., Torrent Pharma, Blue Jet Health, and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Blue Jet Health, Neuland Labs., and Sanofi India, while Good capital structure is found at Torrent Pharma and Sai Life, and Average at Granules India.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while Natco Pharma has a 1-year return of -13.51%, indicating a significantly lower performance compared to its peers. The peer with the lowest 1-year return is Sanofi India at -28.96%. Additionally, the six-month return is negative for Natco Pharma, Torrent Pharma, Neuland Labs., and Sanofi India.

Who are the top shareholders of the Natco Pharma?

The top shareholders of Natco Pharma include promoter V C Nannapaneni with 15.66%, 54 mutual fund schemes holding 1.85%, and 292 foreign institutional investors (FIIs) with 17.49%. Individual investors own 23.68%, while the highest public shareholder is Belgrave Investment Fund at 2.31%, with no pledged promoter holdings.

The top shareholders of Natco Pharma include the promoters, with V C Nannapaneni being the individual with the highest holding at 15.66%. The company has a diverse shareholder base, with 54 mutual fund schemes collectively holding 1.85% and 292 foreign institutional investors (FIIs) holding 17.49%. Additionally, individual investors own 23.68% of the shares, and the highest public shareholder is Belgrave Investment Fund, which holds 2.31%. Overall, the majority of the shares are held by promoters, and there are no pledged promoter holdings.

How big is Natco Pharma?

As of 24th July, Natco Pharma Ltd. has a market capitalization of 18,196.00 Cr, with recent net sales of 4,429.50 Cr and net profit of 1,885.40 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Natco Pharma Ltd. has a market capitalization of 18,196.00 Cr, categorizing it as a Mid Cap company. <BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 4,429.50 Cr, while the sum of Net Profit for the same period is 1,885.40 Cr. <BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 5,853.10 Cr and Total Assets valued at 6,886.90 Cr.

How has been the historical performance of Natco Pharma?

Natco Pharma has shown significant financial growth from March 2020 to March 2025, with net sales increasing from INR 1,915 crore to INR 4,429.50 crore, and profit after tax rising from INR 458.10 crore to INR 1,883.40 crore, reflecting improved operational efficiency and enhanced shareholder value. Total assets also grew from INR 4,587.80 crore to INR 8,580.70 crore during this period.

Answer:<BR>The historical performance of Natco Pharma shows significant growth in various financial metrics over the years.<BR><BR>Breakdown:<BR>Natco Pharma's net sales have steadily increased from INR 1,915.00 crore in March 2020 to INR 4,429.50 crore in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from INR 1,915.00 crore in March 2020 to INR 4,429.50 crore in March 2025. The company's operating profit (PBDIT) also saw substantial growth, climbing from INR 690.00 crore in March 2020 to INR 2,550.50 crore in March 2025, indicating improved operational efficiency. Profit before tax surged from INR 568.70 crore in March 2020 to INR 2,291.40 crore in March 2025, while profit after tax increased from INR 458.10 crore to INR 1,883.40 crore during the same period. The earnings per share (EPS) rose dramatically from INR 25.32 in March 2020 to INR 105.33 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from INR 4,587.80 crore in March 2020 to INR 8,580.70 crore in March 2025, with total liabilities increasing from INR 4,587.80 crore to INR 8,580.70 crore as well. Cash flow from operating activities improved significantly, reaching INR 1,696.00 crore in March 2025, compared to INR 417.00 crore in March 2020. Overall, Natco Pharma has demonstrated robust financial growth and operational performance over the years.

Is Natco Pharma overvalued or undervalued?

As of November 17, 2025, Natco Pharma is considered an attractive investment opportunity, trading at a PE ratio of 9.55 and showing potential for growth with favorable valuation metrics compared to peers, despite recent underperformance against the Sensex.

As of 17 November 2025, Natco Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.55, an EV to EBIT of 7.93, and a ROCE of 25.97%. These ratios suggest that Natco Pharma is trading at a discount compared to its peers, particularly when compared to Sun Pharma, which has a PE ratio of 36.69, and Divi's Lab, with a PE ratio of 69.78.<BR><BR>In the context of its peer group, Natco Pharma's valuation metrics stand out as more favorable, especially with a PEG ratio of 0.00, indicating potential for growth without the corresponding high valuation. While the stock has underperformed the Sensex over the past year, it has shown resilience with a 3-year return of 43.82%, suggesting that it may be positioned for recovery. Overall, Natco Pharma appears to be a compelling investment opportunity within the pharmaceuticals and biotechnology sector.

Is Natco Pharma technically bullish or bearish?

As of December 3, 2025, Natco Pharma's trend is sideways with mixed signals: weekly indicators suggest mild bullishness while monthly indicators are bearish, indicating a lack of strong momentum.

As of 3 December 2025, the technical trend for Natco Pharma has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different time frames. The weekly MACD and KST indicate a mildly bullish outlook, while the monthly MACD and KST are bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands are bullish weekly but mildly bearish monthly. Daily moving averages are mildly bearish. Overall, the indicators suggest a lack of strong momentum in either direction, reflecting the sideways trend.

Are Natco Pharma Ltd. latest results good or bad?

Natco Pharma Ltd.'s latest results are unfavorable, showing a 52.51% decline in net sales and a 70.78% drop in net profit quarter-on-quarter, despite year-on-year growth. The volatility in revenue and reliance on irregular income raise concerns about the sustainability of its earnings.

Natco Pharma Ltd.'s latest results reveal a challenging situation for the company. In the third quarter of FY26, the company reported a significant decline in both net sales and net profit. Specifically, net sales fell by 52.51% quarter-on-quarter to ₹647.30 crores, while net profit dropped by 70.78% to ₹151.50 crores. This sharp contraction raises concerns about the sustainability of its earnings and operational consistency.<BR><BR>Despite a year-on-year improvement in revenues and profits—up 36.33% and 13.91% respectively—this growth is largely attributed to a weak comparison base from the previous year. The volatility in revenue, characterized by large swings from quarter to quarter, suggests that Natco's business model may rely heavily on irregular contract manufacturing deals or one-time product launches rather than stable, recurring revenue streams.<BR><BR>The market reacted negatively to these results, with the stock declining by 1.28% following the announcement. Over the past year, Natco's stock has underperformed significantly, down 30.97%, which reflects broader investor concerns about its earnings predictability.<BR><BR>While the company maintains a strong balance sheet with no long-term debt and a solid return on equity of 17.79%, the extreme revenue volatility and reliance on non-operating income raise questions about the quality and sustainability of its earnings. Overall, the latest results can be considered unfavorable, highlighting the need for improved consistency in performance moving forward.

Has Natco Pharma Ltd. declared dividend?

Yes, Natco Pharma Ltd. has declared a dividend of 75% (₹1.5 per share) with an ex-date of February 18, 2026. While the company shows a strong total return of 57.75% over three years, shorter-term returns have been negative.

Natco Pharma Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 75%<BR>- Amount per share: 1.5<BR>- Ex-date: 18 Feb 26<BR><BR>Dividend Yield: 0.6%<BR><BR>Total Returns by Period:<BR>Over the 3-month period, the price return was -0.48%, the dividend return was 0.37%, resulting in a total return of -0.11%.<BR><BR>In the 6-month period, the price return was -9.07%, the dividend return was 0.57%, leading to a total return of -8.5%.<BR><BR>For the 1-year period, the price return was -15.54%, the dividend return was 0.60%, culminating in a total return of -14.94%.<BR><BR>During the 2-year period, the price return was -4.11%, the dividend return was 1.19%, resulting in a total return of -2.92%.<BR><BR>In the 3-year period, the price return was 53.95%, the dividend return was 3.80%, leading to a total return of 57.75%.<BR><BR>For the 4-year period, the price return was -10.84%, the dividend return was 3.07%, culminating in a total return of -7.77%.<BR><BR>In the 5-year period, the price return was -3.79%, the dividend return was 3.69%, resulting in a total return of -0.1%.<BR><BR>Overall, while Natco Pharma Ltd. has declared a substantial dividend, the total returns over various periods show a mixed performance, with significant negative returns in the shorter terms but a strong positive return over the longer three-year period.

Should I buy, sell or hold Natco Pharma Ltd.?

Why is Natco Pharma Ltd. falling/rising?

As of 05-May, Natco Pharma Ltd. is seeing a stock price increase to 1,124.00, driven by strong historical performance, positive market sentiment, and increased investor participation. The stock is near its 52-week high and has outperformed the broader market significantly.

As of 05-May, Natco Pharma Ltd. is experiencing a rise in its stock price, currently at 1,124.00, reflecting an increase of 10.4 points or 0.93%. This upward movement can be attributed to several key factors. <BR><BR>Firstly, the stock has shown strong performance over various time frames, with a 1-week increase of 2.73%, a 1-month rise of 9.35%, and a year-to-date gain of 24.40%. In the past year, it has outperformed the broader market, generating a return of 31.22% compared to a decline of 4.68% in the Sensex. Additionally, over the past three years, Natco Pharma has achieved an impressive 84.96% increase, significantly surpassing the Sensex's 26.15% gain.<BR><BR>Today, the stock is close to its 52-week high, just 0.26% away from Rs 1,134.9, and has outperformed its sector by 1.28%. It has also been on a positive trend, gaining for the last three days with a total return of 3.5% during this period. The stock is trading above its moving averages across multiple time frames, indicating a strong bullish trend.<BR><BR>Moreover, there has been a notable increase in investor participation, with delivery volume rising by 71.72% compared to the 5-day average. This suggests heightened interest and confidence among investors. The stock's liquidity is also favorable, allowing for substantial trade sizes.<BR><BR>In terms of fundamentals, Natco Pharma boasts high management efficiency with a return on equity (ROE) of 16.25% and is net-debt free, which enhances its attractiveness to investors. The company has a strong institutional presence, with holdings at 22.83%, indicating confidence from larger investors who typically have more resources to analyze company fundamentals.<BR><BR>Overall, the combination of strong historical performance, positive market sentiment, increased investor participation, and solid fundamentals contributes to the rising stock price of Natco Pharma Ltd.

Which are the latest news on Natco Pharma?